Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16074
Title: Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting
Austin Authors: Huynh, Andrew Liem Hieu;Baker, Scott T ;Stewardson, Andrew J;Johnson, Douglas F
Affiliation: Department of General Medicine, Austin Health, Heidelberg, Victoria, Australia
Issue Date: Nov-2016
metadata.dc.date: 2016-06-03
Publication information: Pharmacoepidemiology and Drug Safety 2016; 25(11): 1275-1278
Abstract: Purpose Denosumab-associated hypocalcaemia (DAH) has been reported in patients with osteoporosis or metastatic bone disease and is associated with stages 4 and 5 chronic kidney disease (CKD, estimated glomerular filtration rate <30 mL/min/1.73m2). Other risk factors for hypocalcaemia have not been fully elucidated. We aimed to investigate the incidence of hypocalcaemia amongst patients receiving denosumab and to identify clinical features associated with this adverse event. Methods Retrospective cohort study between June 2013 and June 2014 of patients administered denosumab (60/120 mg) at a tertiary hospital in Melbourne, Australia, to identify the incidence of an albumin-adjusted serum calcium concentration <2.10 mmol/L or ionized calcium <1.13 mmol/L within 6 months of treatment. Univariable and multivariable logistic regression analyses were performed to identify clinical features associated with DAH. Results One hundred and fifty-five patients were administered denosumab (100 osteoporosis, 55 bone metastases). Twenty-two patients (14% [95%CI 9.1–20.7]) developed hypocalcaemia: 55% were men, and 55% had osteoporosis. Eighty-six per cent had a 25-hydroxyvitamin D concentration >50 nmol/L, and 91% were on calcium/colecalciferol supplementation. Stages 4 and 5 CKD (adjusted odd ratio [aOR] 4.71, 95%CI 1.61–13.79, p = 0.005) and male sex (aOR 4.30, 95%CI 1.69–10.96, p = 0.002) were associated with DAH. No patients were documented as having hypocalcaemic symptoms. One patient received intravenous calcium gluconate treatment. Conclusions The incidence of denosumab-associated hypocalcaemia was 14% (95%CI 9.1–20.7) within 6 months of treatment despite widespread use of appropriate calcium/colecalciferol supplementation. Stages 4 and 5 CKD and male sex were associated with subsequent hypocalcaemia.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16074
DOI: 10.1002/pds.4045
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27255807
Type: Journal Article
Subjects: Chronic kidney disease
Denosumab
Hypocalcaemia
Matastatic bone disease
Osteoperosis
Pharmacoepidemiology
Appears in Collections:Journal articles

Show full item record

Page view(s)

2
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.